In CLL, sorafenib inhibits in vitro leukemic cell survival by downregulating IGF-1-R expression and phosphorylation and thus counteracting IGF-1’s binding to its receptor [162] (Table 1). This evidence concerns the gene IGF1 and B-cell chronic lymphocytic leukemia.